(MedPage Today) — SAN FRANCISCO — Intravenous efgartigimod (Vyvgart) met its primary endpoint in adults with acetylcholine receptor (AChR) antibody-negative myasthenia gravis, the ADAPT SERON trial showed.
At week 4, Myasthenia Gravis Activities…
Source link : https://www.medpagetoday.com/meetingcoverage/aanem/118255
Author :
Publish date : 2025-10-31 15:11:00
Copyright for syndicated content belongs to the linked Source.
